News of Pharmaceuticals | Healthcare | Wellness in Gujarat

LAURUS LABS acquires 100% stake in SOUTH AFRICAN pharma company

VISAKHAPATNAM | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Visakhapatnam (Andhra Pradesh) headquartered pharma company Laurus Labs Ltd said of having acquired 100% stake in a subsidiary company of South Africa based Aspean Pharmacare. The company update as submitted to the Indian Bourses read that, Laurus Labs

LUPIN gets nod to sell HIGH BLOOD-PRESSURE treatment tablets in CANADA

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press-release submitted to the Indian Stock Exchanges, Mumbai headquartered pharma company Lupin Ltd said of having got nod from Canadian Pharma Regulator – Health Canada, to market tablets to treat high blood-pressure. In a press-release as addressed to the Indian Bourses titled – “Lupin Receives Health Canada

UK REGULATORS reinstate full GMP status for INDOCO REMEDIES’ Goa plant

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Mumbai headquartered pharma company Indoco Remedies Ltd said of full GMP (Good Manufacturing Practice) status being reinstated at Indoco Remedies Ltd’s Goa plant. In a press-communication as addressed by the company to the Indian Bourses titled – “UK-MHRA reinstates

STRIDES PHARMA acquires majority stake in A SWISS PHARMA COMPANY

BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Bengaluru headquartered Indian Pharma Major Strides Pharma Sciences Ltd said of one of its stepdown subsidiary acquired major stake in tune of 70% in European Pharma Company based out of Switzerland, investing CHF (Swiss Franc) 2.2 million

LUPIN gets USFDA nod to market drug to treat Heart, Liver & Kidney disorders

BALTIMORE (US) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Mumbai headquartered pharma company Lupin Ltd said of having got USFDA nod to market drug to treat heart, liver and kidney related disorders. In a press-communication submitted to the Indian Bourses, titled – “Lupin receives U.S.

GLENMARK PHARMA gets USFDA nod to market SKIN-TREATMENT product

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Mumbai headquartered Glenmark Pharmaceuticals Ltd said of having got final approval from US FDA (Food & Drugs Administration) to sell dermatology (skin-treatment) product. The press-release as submitted by the company to the Indian Stock Exchanges – titled, “Glenmark Pharmaceuticals

UNICHEM LABS gets USFDA nod to market URINARY disorder treatment

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Mumbai headquartered Unichem Laboratories Ltd said of having got nod from US FDA (Food & Drugs Administration) to market drug to treat urinary disorders. The company statement submitted to the Indian Bourses read that, Unichem Laboratories Limited is pleased to

STRIDES PHARMA acquires USFDA approved manufacturing facility in the US

BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Bengaluru & Mumbai headquartered Indian Pharma Major, Strides Pharma Science Ltd said of having acquired US FDA (Food & Drugs Admininstration) approved manufacturing facility at Riviera Beach (Florida) in The United State of America. The press-release as

FRENCH Regulators certify WOCKHARDT’s Ankleshwar plant

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Exchanges, Mumbai headquartered Indian Pharma & Health & Wellness company Wockhardt Ltd said of its Ankleshwar not having compliance certification from French National Agency for Medicines and Health Products safety The company update as addressed to the Indian Bourses, read that

GLENMARK gets USFDA nod to market medicine to treat BREAST-CANCER

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update filing sumitted to the Indian Stock Exchanges, Mumbai headquartered Indian Pharma company Glenmark Pharmaceuticals Ltd said of having got approval from US FDA (Food & Drugs Administration) to market injections to treat breast-cancer. The press-communication submitted by the company to the Indian Bourses titled –

INFOSYS, ILLINOIS UNIVERSITY enter partnership for PRECISION MEDICINE

ROCHESTER (MINNESOTA – US) | BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Bengaluru headquartered Indian Information Technology sector major Infosys Ltd said of having entered into strategic partnership with University of Illinois for precision medicine. The press-release as submitted by the company to the

LUPIN launches anti-depressant drug

BALTIMORE (US) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Mumbai headquartered pharma major Lupin Ltd said of having launched anti-depressant drug of which the approval to market the product, was received earlier from US FDA (Food & Drugs Administration). The press-communication as addressed to the

LUPIN inks pact to sell-off its JAPANESE Injectables biz & related assets

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Mumbai headquartered Indian Pharma major Lupin Ltd said of inking definitive agreement for selling-off its Japanese injectables business and related assets in Japan, to Neopharma Group. The company-statement as addressed by the company to the Indian Bourses, titled –

BIOCON MALAYSIAN facility’s Insulin Glargine mfg unit gets EU GMP certification

BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Bengaluru headquartered Bio-technology major Biocon Ltd said of its Malaysian set-up’s Insulin Glargin Manufacturing facility having received European Union’s (EU) Good Manufacturing Practice (GMP) certification. The press-communication submitted by the company to the Indian Bourses – titled

Cadila gets USFDA nod to market blood-pressure, heart disease treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Stock Exchanges, Ahmedabad headquartered pharma major Cadila Healthcare Ltd (Dr. Pankaj Patel led Zydus Cadila Group) said of having got approval from US FDA (Food & Drugs Administration) to market tablets to treat blood-pressure and heart disease. The press-statement, as addressed by

Zydus announces patient enrollment in clinical trials of Saroglitazar

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Ahmedabad headquartered Indian Pharma major Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Group) said of having enrolled patient(s) in evidences VII phase 2 clinical trial of Saroglitazar Magnesium. The company-statement submitted to the Indian Bourses, titled – “Zydus